TY - JOUR
T1 - Prognostic value of early postoperative tumor marker response in gastric cancer
AU - Nam, Dong Hyuk
AU - Lee, Yong Kang
AU - Park, Jun Chul
AU - Lee, Hyuk
AU - Shin, Sung Kwan
AU - Lee, Sang Kil
AU - Lee, Yong Chan
AU - Cheong, Jae Ho
AU - Hyung, Woo Jin
AU - Noh, Sung Hoon
AU - Kim, Choong Bai
N1 - Funding Information:
ACKNOWLEDGMENT Supported in part by a faculty research Grant of Yonsei University College of Medicine for 2010 (6-2010-0145).
PY - 2013/11
Y1 - 2013/11
N2 - Background: The clinical usefulness of tumor markers as predictors of treatment outcome in patients with stomach cancer after radical gastrectomy has been poorly defined. The purpose of this study was to evaluate a comprehensive understanding of the impact of early postoperative tumor marker normalization on survival after gastrectomy. Methods: Between January 2001 and December 2007, we enrolled 206 patients who had received radical gastrectomy as an initial treatment and had elevated carcinoembryonic antigen (CEA) (>5 ng/mL) or carbohydrate antigen (CA) 19-9 (>37 U/mL) levels. Early tumor marker response was defined as a normalization of preoperative CEA or CA19-9 values 1-2 months after gastrectomy. Results: The mean patient age was 61 years (range 29-84 years), and 139 patients (67.5 %) were male. Early tumor marker response was identified in 150 of 206 (72.8 %) patients. Of the patients, 49 (23.8 %), 41 (19.9 %), and 116 (56.4 %) were stages I, II, and III, respectively, according to the seventh edition of the American Joint Commission on Cancer (AJCC) staging system. Both disease-free survival (DFS) and overall survival (OS) were significantly longer in patients with tumor marker response compared with nonresponse (61.5 vs. 37.6 months; P = 0.010 and 71.3 vs. 50.9 months; P = 0.008, respectively). Multivariate analyses showed that high CA19-9 level, early tumor marker response, and tumor, node, metastasis classification system stage were independent predictors of DFS and OS (P < 0.05). Conclusions: Early CEA or CA19-9 normalization after radical gastrectomy is a strong prognostic factor for gastric cancer, especially in patients with high preoperative levels of tumor markers.
AB - Background: The clinical usefulness of tumor markers as predictors of treatment outcome in patients with stomach cancer after radical gastrectomy has been poorly defined. The purpose of this study was to evaluate a comprehensive understanding of the impact of early postoperative tumor marker normalization on survival after gastrectomy. Methods: Between January 2001 and December 2007, we enrolled 206 patients who had received radical gastrectomy as an initial treatment and had elevated carcinoembryonic antigen (CEA) (>5 ng/mL) or carbohydrate antigen (CA) 19-9 (>37 U/mL) levels. Early tumor marker response was defined as a normalization of preoperative CEA or CA19-9 values 1-2 months after gastrectomy. Results: The mean patient age was 61 years (range 29-84 years), and 139 patients (67.5 %) were male. Early tumor marker response was identified in 150 of 206 (72.8 %) patients. Of the patients, 49 (23.8 %), 41 (19.9 %), and 116 (56.4 %) were stages I, II, and III, respectively, according to the seventh edition of the American Joint Commission on Cancer (AJCC) staging system. Both disease-free survival (DFS) and overall survival (OS) were significantly longer in patients with tumor marker response compared with nonresponse (61.5 vs. 37.6 months; P = 0.010 and 71.3 vs. 50.9 months; P = 0.008, respectively). Multivariate analyses showed that high CA19-9 level, early tumor marker response, and tumor, node, metastasis classification system stage were independent predictors of DFS and OS (P < 0.05). Conclusions: Early CEA or CA19-9 normalization after radical gastrectomy is a strong prognostic factor for gastric cancer, especially in patients with high preoperative levels of tumor markers.
UR - http://www.scopus.com/inward/record.url?scp=84886089676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886089676&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-3066-7
DO - 10.1245/s10434-013-3066-7
M3 - Article
C2 - 23807661
AN - SCOPUS:84886089676
SN - 1068-9265
VL - 20
SP - 3905
EP - 3911
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 12
ER -